Skip to content
HowShorted

ROCKET PHARMACEUTICALS, INC. short interest in 2023

In 2023, ROCKET PHARMACEUTICALS, INC.'s disclosed short interest ran from 9.78% of shares outstanding on 13 Jan 2023 to 9.55% on 29 Dec 2023, a change of -0.23 percentage points. The year's high was 11.97% on 31 Mar 2023 and its low 8.99% on 31 Aug 2023, averaging 10.38% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 17.85 days on 14 Jul 2023. Full history: ROCKET PHARMACEUTICALS, INC..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for ROCKET PHARMACEUTICALS, INC. in 2023

2023 in figures

Start of year
9.78% (13 Jan 2023)
End of year
9.55% (29 Dec 2023)
Change
-0.23 pp
High
11.97% (31 Mar 2023)
Low
8.99% (31 Aug 2023)
Average
10.38%
Highest days to cover
17.85 (14 Jul 2023)
SEC filings marked
5

Every report in 2023

ROCKET PHARMACEUTICALS, INC. short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 20239.78%8.35
31 Jan 20239.00%10.00
15 Feb 20239.99%10.59
28 Feb 202310.98%11.19results (8-K), 10-K filed
15 Mar 202311.80%8.39
31 Mar 202311.97%8.88
14 Apr 202310.86%8.71
28 Apr 202310.61%16.83
15 May 202310.07%10.3110-Q filed
31 May 20239.82%13.74
15 Jun 202310.41%12.32
30 Jun 202310.20%7.69
14 Jul 20239.91%17.85
31 Jul 20239.70%12.76
15 Aug 20239.58%14.3210-Q filed
31 Aug 20238.99%16.40
15 Sep 202311.18%2.42
29 Sep 202311.93%8.76
13 Oct 202311.16%9.38
31 Oct 202311.24%10.78
15 Nov 202310.08%9.7010-Q filed
30 Nov 202310.13%15.95
15 Dec 202310.21%7.52
29 Dec 20239.55%9.11

See also: ROCKET PHARMACEUTICALS, INC.'s full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.